Details of the Drug

General Information of Drug (ID: DMODJ40)

• Drug Name: Ethinyl Estradiol
• Synonyms: Aethinyloestradiolum; Aethinyoestradiol; Amenoron; Amenorone; Anovlar; Certostat; Cyclosa; Dicromil; Diprol; Dyloform; Ertonyl; Esteed; Estigyn; Estinyl; Estopherol; Estoral; Estorals; Ethidol; Ethinoral; Ethinylestradiolum; Ethinylestriol; Ethinyloestradiol; Ethynylestradiol; Ethynyloestradiol; Eticyclin; Eticyclol; Eticylol; Etinestrol; Etinestryl; Etinilestradiol; Etinilestradiolo; Etinoestryl; Etistradiol; Etivex; Feminone; Follicoral; Ginestrene; Inestra; Kolpolyn; Linoral; Lynoral; Menolyn; Microfollin; Novestrol; Oradiol; Orestralyn; Orestrayln; Palonyl; Perovex; Primogyn; Prosexol; Spanestrin; Ylestrol; Aethinyoestradiol [German]; Component of Demulen; Component of Oracon; Component of Ortrel; Diogyn E; Effik Brand of Ethinyl Estradiol; Estoral [Orion]; Ethinyl Estradiol Hemihydrate; Ethinyl Estradiol [USP]; Ethinyl Oestradiol Effik; Ethinylestradiol Jenapharm; Ethinyloestradiol [Steroidal oestrogens]; Ethynyl estradiol; Etinilestradiolo [DCIT]; Jenapharm Brand of Ethinyl Estradiol; Microfollin Forte; Organon Brand of Ethinyl Estradiol; PUBERTAL ETHINYL ESTRADIOL STUDY; Primogyn C; Primogyn M; Progynon C; Progynon M; Schering Brand of Ethinyl Estradiol; EE2; Ethinyl E2; Ethy 11; Diognat-E; Diogyn-E; EE(sub 2); Estinyl (TN); Eston-E; Estoral (Orion); Estoral (VAN); Estradiol, Ethinyl; Estradiol, Ethynyl; Ethinyl estradiol (USP); Ethinyl-Oestradiol Effik; Ethinyl-oestranol; Ethinylestradiolum [INN-Latin]; Ethynylestradiol, Ethinyl Estradiol; Etinilestradiol [INN-Spanish]; Hemihydrate, Ethinyl Estradiol; Jenapharm, Ethinylestradiol; Neo-Estrone; Nogest-S; OVULEN-21; OVULEN-28; Ortho-Cyclen; Chee-O-Gen; Chee-O-Genf; Ethinylestradiol (JP15/INN); Ethinylestradiol [INN:BAN:JAN]; Ethinyl Estradiol, (8 alpha)-Isomer; 17 alpha-Ethinylestradiol; 17 alpha-Ethynylestradiol; 17 alpha-Ethynyloestradiol; 17 alpha-ethinyestradiol; 17-Ethinyl-3,17-estradiol; 17-Ethinyl-3,17-oestradiol; 17-Ethinylestradiol; 17-Ethynylestradiol; 17-Ethynyloestradiol; 17-alpha-Ethinyl-17-beta-estradiol; 17-alpha-Ethynyl-17-beta-oestradiol; 17-alpha-Ethynylestradiol; 17-alpha-Ethynylestradiol-17-beta; 17-alpha-Ethynylestradiol-l7-beta; 17-alpha-Ethynyloestradiol-17-beta; 17-alpha-ethynyl estradiol; 17.alpha.-Ethinyl-17.beta.-estradiol; 17.alpha.-Ethinylestradiol; 17.alpha.-Ethynyl-17.beta.-oestradiol; 17.alpha.-Ethynylestradiol; 17.alpha.-Ethynyloestradiol; 17a-Ethynylestradiol; 17alpha-Ethinyl estradiol; 17alpha-Ethinylestradiol; 17alpha-Ethinylestradiol-17beta; 17alpha-Ethynylestradiol; 17alpha-Ethynyloestradiol; 17alpha-Ethynyloestradiol-17beta

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[1]
Female hypogonadism	GA30.6	Approved	[2]
Hot flushes	GA30	Approved	[1]
Obsolete atrophic vulva	N.A.	Approved	[1]

• Therapeutic Class: Estrogens
• Affected Organisms: Humans and other mammals
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 296.4
  Logarithm of the Partition Coefficient (xlogp); 3.7
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 0.4874 +/- 0.1666 mcgh/L [3]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 74.1 +/- 35.6 ng/L [3]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.5 +/- 0.5 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Clearance: The renal clearance of drug is 2.1 L/h [5]
  Elimination: Ethinylestradiol is 59.2% eliminated in the urine and bile, while 2-3% is eliminated in the feces, and over 90% of ethinylestradiol is eliminated as the unchanged parent drug [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 27.7 +/- 34.2 hours [3]
  Metabolism: The drug is metabolized via UGT1A1, UGT1A3, UGT1A4, UGT1A9, and UGT2B7 [7]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.09639 micromolar/kg/day [8]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.014% [9]
  Vd: The volume of distribution (Vd) of drug is 625.3 +/- 228.7 L [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Hepatotoxicity	Not Available	CYP2B	OTDDG81I	[10]
Hepatotoxicity	Not Available	FGF4	OTNVV3ZG	[10]

• Chemical Identifiers:
  Formula: C20H24O2
  IUPAC Name: (8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
  Canonical SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O
  InChI: InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1
  InChIKey: BFPYWIDHMRZLRN-SLHNCBLASA-N
• Cross-matching ID:
  PubChem CID: 5991
  ChEBI ID: CHEBI:4903
  CAS Number: 57-63-6
  UNII: 423D2T571U
  DrugBank ID: DB00977
  TTD ID: D06NXY
  VARIDT ID: DR00103
  INTEDE ID: DR0656
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Agonist	[11]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[12]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[13]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[14]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[14]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[15]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[16]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[17]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
4-aminobutyrate aminotransferase, mitochondrial (ABAT)	OTXAGR7J	GABT_HUMAN	Gene/Protein Processing	[18]
A disintegrin and metalloproteinase with thrombospondin motifs 9 (ADAMTS9)	OTV3Q0DS	ATS9_HUMAN	Gene/Protein Processing	[18]
Activin receptor type-1B (ACVR1B)	OT778HIQ	ACV1B_HUMAN	Gene/Protein Processing	[18]
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Gene/Protein Processing	[18]
ADP-ribosylation factor 3 (ARF3)	OTYYQX85	ARF3_HUMAN	Gene/Protein Processing	[18]
Advanced glycosylation end product-specific receptor (AGER)	OTPY0IH7	RAGE_HUMAN	Gene/Protein Processing	[19]
Aldehyde dehydrogenase 1A1 (ALDH1A1)	OTCUWZKB	AL1A1_HUMAN	Gene/Protein Processing	[18]
Alkaline phosphatase, germ cell type (ALPG)	OTCIM29R	PPBN_HUMAN	Gene/Protein Processing	[18]
Alkaline phosphatase, placental type (ALPP)	OTZU4G9W	PPB1_HUMAN	Gene/Protein Processing	[18]
Amino acid transporter heavy chain SLC3A1 (SLC3A1)	OT56V01A	SLC31_HUMAN	Gene/Protein Processing	[18]

Molecular Expression Atlas of This Drug

• The Studied Disease: Acne vulgaris
• ICD Disease Classification: ED80

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.23E-01	-8.20E-02	-3.22E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	7.69E-01	1.91E-02	5.45E-02
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	9.78E-01	-3.38E-03	-5.71E-02
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	3.44E-01	-1.85E-01	-5.25E-01
Cytochrome P450 1A1 (CYP1A1)	DME	CYP1A1	5.01E-01	-1.01E-02	-6.05E-02
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	9.09E-01	-9.26E-02	-3.68E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	9.85E-01	2.24E-02	7.33E-02

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ethinyl Estradiol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sarecycline	DMLZNIQ	Moderate	Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Sarecycline .	Acne vulgaris [ED80]	[20]
Metreleptin	DM1NOEK	Moderate	Decreased metabolism of Ethinyl estradiol caused by Metreleptin mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[21]
Pioglitazone	DMKJ485	Minor	Increased metabolism of Ethinyl estradiol caused by Pioglitazone mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[22]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Ethinyl estradiol caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[23]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Ethinyl estradiol due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[24]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Ethinyl estradiol due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[24]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Ethinyl estradiol caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[25]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Ethinyl estradiol caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[26]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Ethinyl estradiol caused by Aminophylline.	Asthma [CA23]	[27]
Desipramine	DMT2FDC	Minor	Decreased metabolism of Ethinyl estradiol caused by Desipramine.	Attention deficit hyperactivity disorder [6A05]	[28]
Ofloxacin	DM0VQN3	Moderate	Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Ethinyl estradiol caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[29]
Sparfloxacin	DMB4HCT	Moderate	Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Gemifloxacin	DMHT34O	Moderate	Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Norfloxacin	DMIZ6W2	Moderate	Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[20]
ABT-492	DMJFD2I	Moderate	Decreased absorption of Ethinyl estradiol due to formation of complexes caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[20]
Omadacycline	DMR2J95	Moderate	Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Omadacycline.	Bacterial infection [1A00-1C4Z]	[20]
Levofloxacin	DMS60RB	Moderate	Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Minocycline	DMVN5OH	Moderate	Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Minocycline.	Bacterial infection [1A00-1C4Z]	[20]
Lomefloxacin	DMVRH9C	Moderate	Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Ag-221	DMS0ZBI	Moderate	Decreased metabolism of Ethinyl estradiol caused by Ag-221 mediated inhibition of CYP450 enzyme.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[21]
Pexidartinib	DMS2J0Z	Major	Increased metabolism of Ethinyl estradiol caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[30]
Lapatinib	DM3BH1Y	Moderate	Decreased clearance of Ethinyl estradiol due to the transporter inhibition by Lapatinib.	Breast cancer [2C60-2C6Y]	[31]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Ethinyl estradiol caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[32]
Atorvastatin	DMF28YC	Minor	Decreased metabolism of Ethinyl estradiol caused by Atorvastatin mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[33]
Anisindione	DM2C48U	Moderate	Antagonize the effect of Ethinyl estradiol when combined with Anisindione.	Coagulation defect [3B10]	[34]
Oxtriphylline	DMLHSE3	Moderate	Decreased metabolism of Ethinyl estradiol caused by Oxtriphylline.	Cough [MD12]	[27]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Ethinyl estradiol caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[35]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Ethinyl estradiol caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[36]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Ethinyl estradiol caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[37]
Selegiline	DM6034S	Moderate	Decreased metabolism of Ethinyl estradiol caused by Selegiline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[38]
Clomipramine	DMINRKW	Minor	Decreased metabolism of Ethinyl estradiol caused by Clomipramine.	Depression [6A70-6A7Z]	[28]
Doxepin	DMPI98T	Minor	Decreased metabolism of Ethinyl estradiol caused by Doxepin.	Depression [6A70-6A7Z]	[28]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Ethinyl estradiol caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Ethinyl estradiol caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Ethinyl estradiol caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[41]
Brivaracetam	DMSEPK8	Minor	Increased metabolism of Ethinyl estradiol caused by Brivaracetam mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Ethinyl estradiol caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Ethinyl estradiol caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[41]
Eslicarbazepine	DMZREFQ	Major	Increased metabolism of Ethinyl estradiol caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[41]
Dantrolene	DM1D8XY	Major	Increased risk of hepatotoxicity by the combination of Ethinyl estradiol and Dantrolene.	Fever [MG26]	[43]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Ethinyl estradiol caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[23]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Ethinyl estradiol caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[26]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Ethinyl estradiol caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[26]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Ethinyl estradiol caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[39]
Boceprevir	DMBSHMF	Major	Increased metabolism of Ethinyl estradiol caused by Boceprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[44]
ABT-450	DMFW860	Major	Decreased metabolism of Ethinyl estradiol caused by ABT-450 mediated inhibition of UGT.	Hepatitis virus infection [1E50-1E51]	[29]
Telaprevir	DMMRV29	Major	Increased metabolism of Ethinyl estradiol caused by Telaprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[44]
Rifampin	DMA8J1G	Major	Increased metabolism of Ethinyl estradiol caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[45]
Rifapentine	DMCHV4I	Major	Increased metabolism of Ethinyl estradiol caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[45]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Ethinyl estradiol caused by Atazanavir mediated inhibition of UGT.	Human immunodeficiency virus disease [1C60-1C62]	[21]
BMS-201038	DMQTAGO	Moderate	Decreased metabolism of Ethinyl estradiol caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[23]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Ethinyl estradiol caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[35]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Ethinyl estradiol caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[21]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Ethinyl estradiol caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[46]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Ethinyl estradiol caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[39]
Melatonin	DMKWFBT	Minor	Decreased metabolism of Ethinyl estradiol caused by Melatonin mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[29]
Linaclotide	DM4EGV0	Moderate	Altered absorption of Ethinyl estradiol caused by Linaclotide.	Irritable bowel syndrome [DD91]	[35]
Miltefosine	DMND304	Moderate	Altered absorption of Ethinyl estradiol caused by Miltefosine.	Leishmaniasis [1F54]	[21]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Ethinyl estradiol caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[35]
Brigatinib	DM7W94S	Major	Increased metabolism of Ethinyl estradiol caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[23]
Lurbinectedin	DMEFRTZ	Moderate	Decreased metabolism of Ethinyl estradiol caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[47]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Ethinyl estradiol caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[39]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Ethinyl estradiol caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[48]
Artemether	DM48QOT	Moderate	Increased metabolism of Ethinyl estradiol caused by Artemether mediated induction of CYP450 enzyme.	Malaria [1F40-1F45]	[44]
Calaspargase pegol	DMQZBXI	Moderate	Decreased metabolism of Ethinyl estradiol caused by Calaspargase pegol mediated hepatotoxicity.	Malignant haematopoietic neoplasm [2B33]	[29]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Ethinyl estradiol caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[49]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Ethinyl estradiol caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[39]
LGX818	DMNQXV8	Major	Increased metabolism of Ethinyl estradiol caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[23]
Dabrafenib	DMX6OE3	Major	Increased metabolism of Ethinyl estradiol caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[44]
Exjade	DMHPRWG	Moderate	Increased metabolism of Ethinyl estradiol caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[23]
Carfilzomib	DM48K0X	Major	Additive thrombogenic effects by the combination of Ethinyl estradiol and Carfilzomib.	Multiple myeloma [2A83]	[44]
Romidepsin	DMT5GNL	Moderate	Antagonize the effect of Ethinyl estradiol when combined with Romidepsin.	Mycosis fungoides [2B01]	[43]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Ethinyl estradiol caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[21]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Ethinyl estradiol caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[29]
E-2007	DMJDYNQ	Moderate	Increased metabolism of Ethinyl estradiol caused by E-2007 mediated induction of CYP450 enzyme.	Neuropathy [8C0Z]	[35]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Ethinyl estradiol caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[35]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Ethinyl estradiol caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[50]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Ethinyl estradiol caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[51]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Ethinyl estradiol caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[31]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Ethinyl estradiol caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[52]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Ethinyl estradiol due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[24]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Ethinyl estradiol due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[24]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Ethinyl estradiol and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[53]
Gatifloxacin	DMSL679	Moderate	Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[20]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Ethinyl estradiol due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Ethinyl estradiol due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Ethinyl estradiol due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Ethinyl estradiol due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Ethinyl estradiol due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Ethinyl estradiol caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[21]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Ethinyl estradiol caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[35]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Ethinyl estradiol caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[29]
Armodafinil	DMGB035	Moderate	Increased metabolism of Ethinyl estradiol caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[44]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Ethinyl estradiol caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[35]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Ethinyl estradiol due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[54]

References

• [1] Ethinyl estradiol FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7071).
• [3] An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch. Drug Des Devel Ther. 2017 Mar 10;11:725-731. doi: 10.2147/DDDT.S131123. eCollection 2017.
• [4] BDDCS applied to over 900 drugs
• [5] Ezuruike U, Humphries H, Dickins M, Neuhoff S, Gardner I, Rowland Yeo K: Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach. Clin Pharmacol Ther. 2018 Dec;104(6):1229-1239. doi: 10.1002/cpt.1085. Epub 2018 Apr 27.
• [6] Cargill DI, Steinetz BG, Gosnell E, Beach VL, Meli A, Fujimoto GI, Reynolds BM: Fate of ingested radiolabeled ethynylestradiol and its 3-cyclopentyl ether in patients with bile fistulas. J Clin Endocrinol Metab. 1969 Aug;29(8):1051-61. doi: 10.1210/jcem-29-8-1051.
• [7] Guo W, Reigan P, Siegel D, Ross D: Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action. Drug Metab Dispos. 2008 Oct;36(10):2050-7. doi: 10.1124/dmd.108.022004. Epub 2008 Jul 17.
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [10] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [11] 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
• [12] P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
• [13] Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab Rev. 2004 Oct;36(3-4):497-509.
• [14] The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
• [15] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [16] The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003 Aug;56(2):232-7.
• [17] Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
• [18] The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
• [19] Differential effect of estrogen receptor alpha and beta agonists on the receptor for advanced glycation end product expression in human microvascular endothelial cells. Biochim Biophys Acta. 2005 Sep 30;1745(3):300-9. doi: 10.1016/j.bbamcr.2005.03.012. Epub 2005 Apr 12.
• [20] Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
• [21] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
• [22] Loi CM, Stern R, Koup JR, Vassos AB, Knowlton P, Sedman AJ "Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent." J Clin Pharmacol 39 (1999): 410-7. [PMID: 10197300]
• [23] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
• [24] Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
• [25] Product Information. Ambien (zolpidem). sanofi-aventis, Bridgewater, NJ.
• [26] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
• [27] Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R "Effects of tobacco smoking and oral contraceptive use on theophylline disposition." Br J Clin Pharmacol 16 (1983): 271-80. [PMID: 6626419]
• [28] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
• [29] Cerner Multum, Inc. "Australian Product Information.".
• [30] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [31] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [32] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [33] Product Information. Lipitor (atorvastatin). Parke-Davis, Morris Plains, NJ.
• [34] Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985): 73-83. [PMID: 3987135]
• [35] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [36] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83. [PMID: 9834039]
• [37] Adson DE, Kotlyar M "A probable interaction between a very low-dose oral contraceptive and the antidepressant nefazodone: a case report." J Clin Psychopharmacol 21 (2001): 618-9. [PMID: 11763013]
• [38] Ito D, Amano T, Sato H, Fukuuchi Y "Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease." J Neurol 248 (2001): 533-4. [PMID: 11499649]
• [39] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
• [40] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [41] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM "Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics." Br J Clin Pharmacol 25 (1988): 527-32. [PMID: 3408633]
• [42] Product Information. Briviact (brivaracetam). UCB Pharma Inc, Smyrna, GA.
• [43] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
• [44] Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
• [45] Back DJ, Breckenridge AM, Crawford F, et al. "The effect of rifampicin on norethisterone pharmacokinetics." Eur J Clin Pharmacol 15 (1979): 193-7. [PMID: 37091]
• [46] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [47] Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
• [48] Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
• [49] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [50] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [51] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [52] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [53] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [54] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.